28 patents currently held
2 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
The next term ends in May 2037. from the record
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
0
Ending by 2030
May 2037
Next term end
4
Patent families
When these terms end
Held patents by the year their term ends
notable patents
fee due within 90 days
all others
Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Notable: the highest-ranked patents in this portfolio by citations and family size. Fee due within 90 days: a maintenance fee is due within 90 days of when this page was computed and not yet paid.
Notable patents
Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Notable
Ends Aug 2037 · Medium confidence
Also notable
Ends May 2037 · High confidence
Also notable
Ends Jan 2043 · High confidence
Alpha Polyglutamated Pemetrexed and Uses Thereof
US 11,779,584
Cited by 35 later US patents, top 5% of utility patents granted in 2023 in our data. Protection runs to 2037. A terminal disclaimer caps this term to an earlier patent's.
Targeted Liposomal Gemcitabine Compositions and Methods Thereof
US 10,940,112
The earliest of the three still in force, granted 2021 and renewed since. Its term ends first, in 2037.
Trans-Crocetin Compositions and Treatment Regimens
US 12,622,874
A family of 17 related applications built on the 2026 grant. Too new for citation comparison; protection runs to 2043.
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Jan 18, 2027The maintenance fee for Polyglutamated Antifolates and Uses Thereof (US 11,701,432) comes due Jan 18, 2027. Unpaid by Jul 19, 2027, it lapses early.
- 1 fee due Feb 22, 2027The maintenance fee for Alpha Polyglutamated Pralatrexate and Uses Thereof (US 11,730,738) comes due Feb 22, 2027. Unpaid by Aug 23, 2027, it lapses early.
- 2 fees due Apr 3 to 10, 2027 · next Apr 3
Recent changes
Nothing was recorded against this company's patents in the last 90 days.
What they patent
Grouped by real patent family, largest first, labeled by the earliest filing in each. No technology classification is inferred from titles.
| Alpha Polyglutamated Antifolates and Uses Thereof | 23 in force | to Dec 2039 |
| Carotenoid Compositions and Uses Thereof | 2 in force | to Jan 2043 |
| Targeted Liposomal Gemcitabine Compositions and Methods Thereof | 2 in force | to May 2038 |
| Platinum Complexes and Uses Thereof | 1 in force | to Mar 2039 |
Patents held now
Soonest term end first.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 10,940,112 | Targeted Liposomal Gemcitabine Compositions and Methods Thereof In force · High confidence | In force | High confidence | |
| US 11,344,628 | Alpha Polyglutamated Antifolates and Uses Thereof In force · High confidence | In force | High confidence | |
| US 11,701,432 | Polyglutamated Antifolates and Uses Thereof In force · High confidence | In force | High confidence | |
| US 11,779,584 | Alpha Polyglutamated Pemetrexed and Uses Thereof In force · Medium confidence | In force | Medium confidence | |
| US 12,048,767 | Gamma Polyglutamated Pralatrexate and Uses Thereof In force · High confidence | In force | High confidence | |
| US 12,076,402 | Alpha Polyglutamated Antifolates and Uses Thereof In force · High confidence | In force | High confidence | |
| US 12,128,046 | Alpha Polyglutamated Methotrexate and Uses Thereof In force · High confidence | In force | High confidence | |
| US 12,201,695 | Polyglutamated Pemetrexed and Uses Thereof In force · Medium confidence | In force | Medium confidence | |
| US 12,213,981 | Alpha Polyglutamated Pralatrexate and Uses Thereof In force · Low confidence | In force | Low confidence | |
| US 12,220,431 | Gamma Polyglutamated Antifolates and Uses Thereof In force · High confidence | In force | High confidence |
Also on record, not counted in the 28: 2 patents in force now held by others · 35 applications pending · 8 applications abandoned. List them
Sources and methods
Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Fee due within 90 days marks a patent with a maintenance fee due within 90 days of the date this page was computed and not yet recorded paid, so it can end earlier than the bar shows. A fee left unpaid ends the patent at the close of the six month grace period that follows its due date, not on the due date itself. It is not a prediction that the fee will be missed.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.